Progress in treatment of primary mediastinal large B-cell lymphoma
10.3760/cma.j.cn121090-20230731-00041
- VernacularTitle:原发纵隔大B细胞淋巴瘤的治疗进展
- Author:
Lyuwen CHEN
1
;
Jianyong LI
;
Lei FAN
Author Information
1. 南京医科大学第一附属医院，江苏省人民医院血液科，南京 210029
- From:
Chinese Journal of Hematology
2024;45(1):98-102
- CountryChina
- Language:Chinese
-
Abstract:
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma originating from the thymus, which has different clinical and biological characteristics from diffuse large B-cell lymphoma, NOS. PMBCL tends to occur in young women, usually presenting as a large anterior mediastinal mass. Most patients are in stage Ⅰ-Ⅱ at the time of presentation. There is no standard prognostic scoring system for PMBCL. Immunochemotherapy is commonly used in the treatment of PMBCL, but the optimal first-line treatment has not been determined, and the status of radiotherapy is controversial. The value of PET-CT guided therapy needs to be further verified. Relapsed/refractory PMBCL has a poor prognosis, while novel therapies such as PD-1 inhibitors, brentuximab vedotin, and CAR-T can help improve survival in these patients.
